BCHE and Parkinson disease: In light of these abnormalities, the use of cholinesterase inhibitors is currently the preferred pharmacological treatment strategy for cognitive impairments in PD (Akbar and Friedman, 2015), and evidence from both large, randomized placebo-controlled trials and meta-analyses suggests that use of these compounds may provide at least modest benefit in the treatment of PD-D (Rolinski et al., 2012; Wang et al., 2015).